Advertisement
U.S. markets close in 6 minutes

Cabaletta Bio, Inc. (CABA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.81-2.16 (-9.01%)
As of 03:54PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Outside Bar (Bearish)

Outside Bar (Bearish)

Previous Close23.97
Open23.93
Bid22.18 x 800
Ask22.25 x 800
Day's Range21.54 - 23.98
52 Week Range5.88 - 26.35
Volume518,791
Avg. Volume995,990
Market Cap934.545M
Beta (5Y Monthly)2.46
PE Ratio (TTM)N/A
EPS (TTM)-1.70
Earnings DateMar 14, 2024 - Mar 18, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.44
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CABA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cabaletta Bio, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/20/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • Insider Monkey

    Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4

    Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fourth quarter witnessed a significant easing in financial conditions, which was most notable in the final two months. Class A shares of the fund outperformed the Russell […]

  • GlobeNewswire

    Cabaletta Bio to Participate in Upcoming Investor Conferences in March

    PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in March: TD Cowen 44th Annual Health Care Conference: Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat on Tuesday, March 5, 2024 at 1

  • GlobeNewswire

    Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

    PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, for the treatment of idiopathic inflammatory myopathies (IIM, or my